Article
Immunology
Xin Jin, Wenyi Lu, Meng Zhang, Xia Xiong, Rui Sun, Yunxiong Wei, Xiaoyuan He, Mingfeng Zhao
Summary: This study found that infection temperature affects the phenotype and function of CAR-T cells, recommending infection at 32 degrees for preparing CAR-T cells with a balanced function and phenotype, which have enhanced oncolytic ability.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Xi Zhang, Yu Yang Ng, Zhicheng Du, Zhendong Li, Can Chen, Lin Xiao, Wee Joo Chng, Shu Wang
Summary: Modification of Vγ9Vδ2 T cells with a BCMA-specific CAR enhances their cytotoxicity against multiple myeloma cells, leading to a significant reduction in tumor burden and prolonged survival in a mouse model.
Article
Multidisciplinary Sciences
Caroline Lamarche, Kirsten Ward-Hartstonge, Tian Mi, David T. S. Lin, Qing Huang, Andrew Brown, Karlie Edwards, Gherman E. Novakovsky, Christopher N. Qi, Michael S. Kobor, Caitlin C. Zebley, Evan W. Weber, Crystal L. Mackall, Megan K. Levings
Summary: Regulatory T cells (Tregs) are susceptible to exhaustion, which can limit their therapeutic effect. A comprehensive investigation on exhaustion in Tregs reveals key similarities and differences with exhausted conventional T cells. This finding has important implications for the design of CAR Treg adoptive immunotherapy strategies.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Biotechnology & Applied Microbiology
Christina Amatya, Melissa A. Pegues, Norris Lam, Danielle Vanasse, Claudia Geldres, Stephanie Choi, Stephen M. Hewitt, Steven A. Feldman, James N. Kochenderfer
Summary: CARs targeting SLAMF7 show promise for MM therapy due to specific expression on MM cells, and CD28-containing CARs exhibit superior anti-tumor activity compared to 4-1BB-containing CARs. Inclusion of a suicide gene in SLAMF7-targeting CAR T cells is prudent to eliminate cells expressing SLAMF7 on normal leukocytes when necessary.
Article
Immunology
Ileanet Avalos, Thailin Lao, Elsa Maria Rodriguez, Yasser Zamora, Alianet Rodriguez, Ailyn Ramon, Gilda Lemos, Ania Cabrales, Monica Bequet-Romero, Dionne Casillas, Ivan Andujar, Luis Ariel Espinosa, Luis Javier Gonzalez, Yanitza Alvarez, Yamila Carpio, Mario Pablo Estrada
Summary: COVID-19 is a highly contagious respiratory viral disease caused by the novel coronavirus SARS-CoV-2. Researchers have developed a recombinant protein by fusing the receptor-binding domain (RBD) of the viral protein spike (S) with the extracellular domain of CD154, an immune system modulator molecule. This recombinant protein has shown promising immunogenicity in mice and non-human primates, inducing a specific and high IgG response and neutralizing the virus. It has the potential to enhance the current vaccines against COVID-19.
Article
Oncology
Jordi Pfeifer Serrahima, Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Roeder, Claudia Arndt, Anja Feldmann, Anne Kiefer, Maren Pruefer, Ines Kuehnel, Torsten Tonn, Michael Bachmann, Winfried S. Wels
Summary: Chimeric antigen receptor (CAR)-engineered immune effector cells show promise in cancer immunotherapy, but face challenges of toxicity and immune escape. Adaptor CARs triggered by bispecific molecules that crosslink CAR with tumor-associated antigens may overcome these challenges. In this study, NK cells were genetically modified to express a universal CAR (UniCAR) and redirected to tumor cells using target modules (TMs) containing an ErbB2-specific antibody domain and a UniCAR-recognized peptide. Different TM designs and CAR compositions affected cell killing activity, with TMs carrying two or three E5B9 epitopes being more effective with the first-generation UniCAR, while the second-generation UniCAR was more active with TMs carrying one E5B9 sequence. These findings have implications for the development of optimized UniCAR and TM combinations in cancer immunotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Biotechnology & Applied Microbiology
Laura Syzdykova, Gulzat Zauatbayeva, Viktoriya Keyer, Yerlan Ramanculov, Roman Arsienko, Alexandr V. Shustov
Summary: Viral vectors are essential for advanced therapies such as CAR-T therapy. However, the high price and limited supply of CAR vectors currently restrict their wider use. In this study, a technology for packaging lentiviral vectors using autonomously replicating RNAs was described. This method allows the production of therapeutic amounts of CAR+ cells in an academic setting.
BIOCHEMICAL ENGINEERING JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Kyung-Eun Noh, Jun-Ho Lee, So-Yeon Choi, Nam-Chul Jung, Ji-Hee Nam, Ji-Soo Oh, Jie-Young Song, Han Geuk Seo, Yu Wang, Hyun Soo Lee, Dae-Seog Lim
Summary: Co-expression of CD19 CAR and tTRII-I7R in T cells effectively inhibits recurrence of B cell lymphoma, demonstrating a new strategy for long-lasting anti-tumor effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Mansour Poorebrahim, Isaac Quiros-Fernandez, Frederik Marme, Stefan EG. Burdach, Angel Cid-Arregui
Summary: In this study, the functionality of immune effector cells targeting HPV16-positive cancer cells was enhanced by combining a costimulatory chimeric antigen receptor (CAR) with a T cell receptor (TCR). The results showed improved antigen-specific activation and cytotoxicity of NK cells expressing both E7-TCR and TROP2-CAR. This approach has the potential to improve the outcome of adoptive cell immunotherapies for HPV16+ cancer patients.
Review
Medicine, General & Internal
Xinyue Deng, Jianfeng Zhou, Yang Cao
Summary: Adoptive therapeutic immune cells, such as CAR-T cells and natural killer cells, have revolutionized the treatment of intractable lymphoma. Autologous cells have limitations, so the combination of iPSC technology and CAR design offers a promising strategy to produce controllable and cost-effective live drugs. This review discusses the feasibility, advantages, and drawbacks of this approach, and provides insights into personalized cell-based therapies.
CHINESE MEDICAL JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Rofaida Mostafa Soliman, Keisuke Nishioka, Tomo Daidoji, Osamu Noyori, Takaaki Nakaya
Summary: Considering the limited benefits of re-administration of NDV in immunized individuals, this study generated two types of recombinant chimeric NDVs using APMV-2 F and HN genes, with enhanced immune responses by inserting the human IFN-gamma gene. These chimeric viruses had notable escape ability from NDV antiserum, infected cancer cell lines, and showed potential as a cancer treatment tool.
Article
Cell Biology
May C. I. van Schalkwyk, Sjoukje J. C. van der Stegen, Leticia Bosshard-Carter, Helen Graves, Sophie Papa, Ana C. Parente-Pereira, Farzin Farzaneh, Christopher D. Fisher, Andrew Hope, Antonella Adami, John Maher
Summary: Adoptive cancer immunotherapy using CAR engineered T-cells shows great potential, but faces obstacles in efficient cell product generation under GMP. This study developed a simplified process to generate CAR engineered T-cells, achieving reproducible IL-4-dependent expansion and enrichment under GMP.
Article
Virology
Jinjiao He, Ying An, Jianying Qi, Lin Cui, Kai Yang, Mingyao Liu, Bo Qu, Shijun Yan, Jiechao Yin, Xiaohui Jing, Hui Dong, Qingzhong Yu, Deshan Li, Yunzhou Wu
Summary: Oncolytic virus therapy is a promising breakthrough in cancer treatment, with recombinant NDV/Anh-TRAIL showing potential as a candidate for glioma therapy in this study. The experimental results demonstrated the ability of NDV/Anh-TRAIL to inhibit glioma growth, suggesting it as a potential treatment option.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Cell Biology
Akihiro Ishikawa, Masazumi Waseda, Tomoko Ishii, Mika K. Kaneko, Yukinari Kato, Shin Kaneko
Summary: CAR-T cells with humanized CAR gene sequence have shown improved efficacy against solid tumors, especially when targeting the glycosylated transmembrane protein Podoplanin (PDPN). In this study, anti-PDPN CARs from antibodies NZ-27 or humanized NZ-1 were investigated for enhanced therapeutic potential. The NZ-27 CAR-T cells showed tumor-specific cytotoxicity, proinflammatory cytokine production, and anti-tumor activity against PDPN-expressing tumor xenografts in mice, surpassing the nonhumanized NZ-1 CAR-T cells.
Article
Oncology
Konstantinos Lontos, Yiyang Wang, Supriya K. Joshi, Andrew T. Frisch, McLane J. Watson, Alok Kumar, Ashley Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M. Delgoffe
Summary: This study demonstrates that an engineered version of the inhibitory transcription factor PGC-1 alpha can metabolically reprogram human CAR-T cells, resulting in improved in vivo efficacy for the treatment of solid tumors. In contrast, a truncated version of PGC-1 alpha, NT-PGC-1 alpha, did not improve the in vivo outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
